MMSI Merit Medical Systems Inc.

Merit Medical Launches the PreludeSYNC EZ™ Radial Compression Device

Merit Medical Launches the PreludeSYNC EZ™ Radial Compression Device

Unique band provides precise placement and clear visibility of the access site, optimizing hemostasis for radial artery procedures

SOUTH JORDAN, Utah, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of the PreludeSYNC EZ™ Radial Compression Device.

The new device is the latest in Merit’s ongoing excellence and leadership in advancing transradial access for endovascular patient care. It complements a robust radial portfolio of products that includes the Prelude IDeal™, Merit’s thin-walled hydrophilic sheath introducer with superior kink and compression resistance.1

Designed for optimal clinical performance, the PreludeSYNC EZ assists in achieving access site patent hemostasis (the prevention of bleeding) following radial artery access procedures.

A unique cinch-style wrist band supports controlled and precise two-handed placement, a key feature that differentiates it from other radial compression devices on the market. A large window provides clear visibility designed to further help with precise placement. Created with the patient and clinician in mind,​ the PreludeSYNC EZ provides a simplified alternative to the two-strap compression band currently on the market.

Radial artery access is a minimally invasive approach to diagnosing and treating a wide range of conditions. Through a pinhole-size site in the wrist, a catheter is inserted into the radial artery. Under imaging guidance, the catheter is then threaded through the body’s network of blood vessels to the location needing treatment.

The rate of radial artery access use in the United States is on the rise. Between 2011 and 2018, radial access for diagnostic angiograms (X-ray procedures that show blocked or narrowed vessels in the heart) increased from 17.5% to 60.4%.2 Radial access rates for percutaneous coronary intervention (procedures used to open blocked vessels) also grew from 14.0% to 51.8%.2 Radial coronary angiography and PCI have been linked to better clinical outcomes. 3 Benefits include fewer bleeding complications, improved patient comfort, and decreased procedure costs compared to femoral procedures, or those performed through the femoral artery in the groin.3

“Merit Medical is fully invested in being a leader in radial artery access,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “By listening to physician feedback, we transformed clinical needs into an advanced compression device that complements our expansive portfolio of solutions designed to support radial artery access procedures and deliver better patient care.”

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 500 individuals. Merit employs approximately 6,500 people worldwide.

TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions.

CONTACTS 

PR/Media Inquiries 

Sarah Comstock 

Merit Medical 

|

INVESTOR INQUIRIES 

Mike Piccinino, CFA, IRC 

Westwicke - ICR 

|

  1. Data on File.



  2. Doll JA et al. 2022. “Trends in Arterial Access Site Selection and Bleeding Outcomes Following Coronary Procedures, 2011-2018.” Circ Cardiovasc Qual Outcomes (Mar 11). doi: 10.1161/CIRCOUTCOMES.121.008359. PMID: 35272504.



  3. O’Riordan. 2022. “Radial Access for Angiography and PCI on the Rise in the US.” TCTMD (Mar 16).



 



EN
21/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 95.190USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

Merit Medical Acquires Biolife Delaware, L.L.C.

Merit Medical Acquires Biolife Delaware, L.L.C. Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports.Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profileMerit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to include the projected impact from this acq...

 PRESS RELEASE

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-I...

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial. SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulator...

 PRESS RELEASE

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Ar...

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm cohort of the WAVE trial were presented at the annual Charing Cross Symposium ...

 PRESS RELEASE

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year...

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance First Quarter Highlights† Reported revenue of $355.4 million, up 9.8%Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectivelyGAAP operating margin of 11.5%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.3%, compared to 17.0% in prior year periodGAAP EPS $0.49, up 2.0%Non-GAAP EPS* $0.86, up 14.8%Free cash flow* generation of $19.5 million, down 20.5% † Comparisons above are calculated for the current quarter compared with the first quarter o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch